Maynard, Mass., June 6, 2012 – Allegro Diagnostics today announced its participation in the BIO Business Forum at the BIO International Convention, being held June 18-20 in Boston. Michael D. Webb, President and CEO, will present on Wednesday, June 20 at 2:15 p.m. EDT in room 104C of the Boston Convention and Exhibition Center. Mr. Webb will provide an overview of Allegro’s molecular testing platform for the early detection of lung cancer, as well as its lead genomic test, BrochoGen™.
About the Allegro Platform
Allegro Diagnostics’ molecular testing platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. The “field of injury” principle on which the platform is based refers to the common molecular response that occurs throughout the respiratory tract in current and former smokers with lung cancer. These changes can be detected in a gene expression signature from non-malignant airway cells and indicate the presence of malignancy remotely in the lung. Allegro has applied this platform to generate multiple product candidates.
About Allegro Diagnostics
Allegro Diagnostics is a molecular diagnostics company focused on the development and commercialization of innovative genomic tests for the diagnosis, staging and informed treatment of lung cancer and other lung diseases. Allegro has developed a molecular testing platform that utilizes a genomic biomarker to detect early signs of lung cancer in current and former smokers. The company’s lead product is the BronchoGen™ genomic test for use in combination with standard bronchoscopy for the diagnosis of lung cancer. www.allegrodx.com
MacDougall Biomedical Communications